Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
Open accessThe DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index; 6 of the 44 sources its claims cite were checked for support.
Abstract
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.
Overview
CoChat Summary
## TL;DR
Lutathera® ([177Lu]Lu-DOTA-TATE) is presented as the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy (PRRT) for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors. The paper summarizes its mechanism, indication, dosing, manufacturing, and the clinical trial results that supported approval.
## Key findings
- Lutathera® was approved by the EMA in 2017 and the FDA in 2018; the paper also notes Canadian approval in 2019.
- Its active ingredient is [177Lu]Lu-DOTA-TATE, which combines lutetium-177 with the somatostatin analogue DOTA-TATE to target SSTR-expressing tumor cells and cause DNA single- and double-strand breaks.
- The recommended treatment schedule is four infusions of 7.4 GBq every 8 weeks; intervals may be extended to 16 weeks if dose-modifying toxicity occurs.
- In the NETTER-1 phase III trial (229 patients), progression-free survival favored [177Lu]Lu-DOTA-TATE plus octreotide LAR over high-dose octreotide LAR: 65% vs 11% of patients were progression-free at 20 months (p < 0.0001), median PFS was not reached vs 8.5 months, and objective response rate was 18% vs 3% (p < 0.001).
## Methods
- Narrative review/overview of Lutathera® covering chemical properties, clinical indication, application, pharmacology/pharmacokinetics, manufacturing, and regulatory status.
- Draws on published clinical studies and product monographs, including the Erasmus phase I/II study (1,214 patients) and the NETTER-1 phase III trial (229 patients).
- Summarizes reported trial endpoints and pharmacokinetic/dosimetry data from the cited studies rather than presenting new original analyses.
## Limitations
- The paper does not report any new original experimental or clinical data; it synthesizes prior literature and regulatory documents.
- The text makes evident that some sections are only brief summaries and refer readers to product monographs or cited studies for details; this limits methodological depth and reproducibility of the review’s own synthesis.
- Not stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
5 Valid · 0 Not valid · 33 Not checked · 1 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The positive results of the multicenter phase-III clinical trial [16], NETTER-1, comparing the treatment with [177Lu]Lu-DOTA-TATE to the treatment with high doses of octreotide LAR, paved the way for its approval by national and international medicines agencies in America and Europe.”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 4. Conclusions
What the sources say
- Partly supportedcites [16] Strosberg, 2017, NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 3. Medicinal and Pharmaceutical Overview > 3.3. Pharmacology and Pharmacokinetics In a study by Reubi et al. [29], the SSTR subtype affinity profile of a number of somatostatin analogues was investigated, showing, e.g., that DOTA-TATE exhibits high affinity for human SSTR2 (IC50 of 1.5 ± 0.4 nM) with much less binding affinity for all other human SSTRs. Complexing this peptide with yttrium resulted in a comparable binding affinity profile and complexing with gallium in an even higher affinity for SSTR2 (IC50 of 0.2 ± 0.04 nM). [177Lu]Lu-DOTA-TATE shows high binding affinity for SSTR2 as well, and therefore binds to malignant cells with an upregulation of SSTR2 [8]. Upon binding to the receptor, the radiolabeled peptide becomes internalized into the cell and the β particle emission of 177Lu induces DNA single- and double-strand breaks, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions [8]. Figure 2 gives a simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE. Due to the range of the β particles in comparison to the diameter of a cell, the emitted β particles traverse several cells (10–1000) [30]. This effect has been termed “cross-fire effect” and is responsible for the possible destruction of multiple cells in the vicinity of the tracer-accumulating cell [31]. Using β particle emitters, the cross-fire effect is critical for the improvement of tumor dose homogeneity and for ensuring a sufficient dose for each cell [32]. Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31]. Owing to the nanomolar concentration (10 µg/mL; 6.3 × 10−3 nM) of the peptide in the sterile injection solution [8], no clinically relevant pharmacodynamic effects are expected. The pharmacokinetic properties of Lutathera® are described in the product monographs [8,27]. [177Lu]Lu-DOTA-TATE is immediately and completely bioavailable through i. v. injection and clears rapidly from blood. The effective half-life in blood in a study with 31 patients was determined to be 0.31 ± 0.13 h [33]. The effective blood elimination half-life is 3.5 ± 1.4 h [26]. Studies using non-radioactive [175Lu]Lu-DOTA-TATE showed that protein binding to human plasma is ca. 50% and that transchelation of lutetium to serum proteins is not occurring. Four hours after administration, [177Lu]Lu-DOTA-TATE shows uptake in kidneys, tumoral lesions, liver, and spleen, and in some patients, additionally in the pituitary gland and thyroid. Kidney uptake can be decreased by co-administration of amino acids (see above), which reduces the re-absorption of the radiopharmaceutical through the proximal tubules [34]. This is mandatory because the compound is primarily eliminated through the renal system. Data from the Erasmus phase-I/-II and NETTER-1 phase-III trials indicate that ca. 60% of the radiopharmaceutical is eliminated in the urine within 24 h post injection (p. i.) and ca. 65% within 48 h p. i. Metabolism of [177Lu]Lu-DOTA-TATE is negligible, as shown by radio-HPLC analysis of urine samples collected 48 h p. i. Radiation dosimetry of [177Lu]Lu-DOTA-TATE has been evaluated in 20 patients in clinical studies [15,27]. The critical organ is the bone marrow. However, with the recommended cumulative dose of 29.6 GBq (4 × 7.4 GBq), neither correlation of hematological toxicity with total administered radioactivity nor with bone marrow absorbed dose has been observed. The kidney is not a critical organ when co-administration of appropriate amino acids is conducted. The median radiation dose to the kidneys can be reduced by 47% (34% to 59%) with co-administration of amino acids [26]. Table 1 summarizes estimated radiation absorbed doses for Lutathera® in the NETTER-1 trial for main organs [26,27].
What the sources say
- Supportedcites [31] Haberkorn, 2017, The Future of Radioligand Therapy: α, β, or Both?, J. Nucl. Med. source
The discussion of the radiation-induced bystander effect (p. 1) explicitly defines it as neighboring cells that were not directly exposed to ionizing radiation behaving as though they were exposed. The Figure 1 caption (p. 2) likewise describes effects on neighboring, unexposed cells. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim could be matched to a paper, so there is nothing to check it against.
In the paper
“The clinical indication of Lutathera® is the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2 grade) SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults [15,27].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 3. Medicinal and Pharmaceutical Overview > 3.1. Clinical Indication
What the sources say
- Not matchedcites [15] (2019, April 23). Lutathera® Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf.
We searched by its title and found no matching paper.
- Not matchedcites [27] (2019, April 23). Product Monograph for LUTATHERATM for Canada. Available online: https://pdf.hres.ca/dpd_pm/00049099.pdf.
We searched by its title and found no matching paper.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“It could also be demonstrated that treatment with [177Lu]Lu-DOTA-TATE was safe and well tolerated [8].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 1. Introduction
What the sources say
- Not matchedcites [8] (2019, April 18). Product Monograph LUTATHERA®. Available online: https://www.samnordic.se/wp-content/uploads/2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
We searched by its title and found no matching paper.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Using the concept of PRRT, Lutathera® combines the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors.”
- Also stated in: § 4. Conclusions · plain
“Combining the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, [177Lu]Lu-DOTA-TATE delivers ionizing radiation specifically and selectively to tumor cells expressing SSTRs.”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > Abstract
What the sources say
- Not matchedcites [8] (2019, April 18). Product Monograph LUTATHERA®. Available online: https://www.samnordic.se/wp-content/uploads/2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
We searched by its title and found no matching paper.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 4. Conclusions · plain
12 more claims
Create a free account to see all 39 claims and to verify the 4 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 3
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532 · cited 1×
“The development of these radiolabeled somatostatin ligands was a very long scientific journey that started with the first description of somatostatin more than 45 years ago [10].”
BackgroundPhase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
Krenning, E. P., Breeman, W. A. P., Kooij, P. P. M., Lameris, J. S., Bakker, W. H., Koper, J. W., Ausema, L., Reubi, J. C., & Lamberts, S. W. J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91258-0 · Cited by 625 · cited 1×
“The first radiolabeled SST analog used for imaging was [123I, Tyr3]octreotide in 1989 [12], while early therapeutic studies used [111In]In-DTPA-octreotide in the mid to late 1990s, since other chelated somatostatin ligands were not available [11].”
MethodSomatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0078 · Cited by 466 · cited 1×
“The first radiolabeled SST analog used for imaging was [123I, Tyr3]octreotide in 1989 [12], while early therapeutic studies used [111In]In-DTPA-octreotide in the mid to late 1990s, since other chelated somatostatin ligands were not available [11].”
MethodAntibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
Consensus nomenclature rules for radiopharmaceutical chemistry — Setting the record straight
Coenen, H. H., Gee, A. D., Adam, M., Antoni, G., Cutler, C. S., Fujibayashi, Y., Jeong, J. M., Mach, R. H., Mindt, T. L., Pike, V. W., et al. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.09.004 · Cited by 226 · cited 1×
“In January 2018 (26 January 2018), Lutathera® ([177Lu]Lu-DOTA-TATE (for rules on nomenclature, see [1,2])) was approved by the FDA [3] for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.”
BackgroundElschot, M., Vermolen, B. J., Lam, M. G. E. H., de Keizer, B., van den Bosch, M. A. A. J., & de Jong, H. W. A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055742 · Cited by 209
Targeted α-therapy–past, present, future?
Brechbiel, M. W. (2007) · Dalton Transactions · doi:10.1039/b704726f · Cited by 151
Crystal structure and solution dynamics of the lutetium(III) chelate of DOTA
Aime, S., Barge, A., Botta, M., Fasano, M., Danilo Ayala, J., & Bombieri, G. (1996) · Inorganica Chimica Acta · doi:10.1016/0020-1693(96)05130-4 · Cited by 148
Research works printed but not linked: 3
- Erion, 1999, High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model [abstract], J. Nucl. Med., 40, 223
- Nagy, 2004, Radionuclide Therapy, Handbook of Nuclear Chemistry, Volume 4, 315
- Rolleman, 1996, Inhibition of Renal Uptake of Indium-111-DTPAOctreotide, J. Nucl. Med., 37, 1388
Cited by
Items 101–200 of 426
Brossard, C., Vlach, M., Vène, É., Ribault, C., Dorcet, V., Noiret, N., Loyer, P., Lepareur, N., & Cammas‐Marion, S. (2021) · Nanomaterials · doi:10.3390/nano11040958 · Cited by 21
Lee, D. Y., & Kim, Y.-I. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003110 · Cited by 23
Zhao, L., Pang, Y., Wang, Y., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05587-7 · Cited by 21
Bassi, G., Favalli, N., Pellegrino, C. E., Onda, Y., Scheuermann, J., Cazzamalli, S., Manz, M. G., & Neri, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01103 · Cited by 22
Therapeutic options in thymomas and thymic carcinomas
Muto, Y., & Okuma, Y. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2052278 · Cited by 21
Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies
Lau, J., Lee, H., Rousseau, J., Bénard, F., & Lin, K. (2022) · Molecules · doi:10.3390/molecules27154959 · Cited by 22
Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update
Franco, M. D., Zanoni, L., Fortunati, E., Fanti, S., & Ambrosini, V. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01526-5 · Cited by 25
“According to EMA, [177Lu]Lu-DOTATATE is approved for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SST-positive GEP NET in adults [7].”
BackgroundMethodPYTA: a universal chelator for advancing the theranostic palette of nuclear medicine
Simms, M. E., Li, Z., Sibley, M. M., Ivanov, A. S., Lara, C. M., Johnstone, T. C., Kertész, V., Fears, A., White, F. D., Thorek, D. L. J., et al. (2024) · Chemical Science · doi:10.1039/d3sc06854d · Cited by 21
Cyclotron-produced 68Ga from enriched 68Zn foils
Siikanen, J., Jussing, E., Milton, S., Steiger, C., Ulin, J., Jonsson, C., Samén, E., & Tran, T. A. (2021) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2021.109825 · Cited by 22
Brandt, F., Ullrich, M., Wodtke, J., Kopka, K., Bachmann, M. P., Löser, R., Pietzsch, J., Pietzsch, H., & Wodtke, R. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01472 · Cited by 21
Self-citationHan, G., Hwang, E., Lin, F., Clift, R., Kim, D., Guest, M., Bischoff, E. D., Moran, S. E., & Li, G. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0029 · Cited by 28
Pamshong, S. R., Bhatane, D., Sarnaik, S., & Alexander, A. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113613 · Cited by 21
Siebinga, H., der Veen, B. J. D. W., Beijnen, J. H., Stokkel, M. P. M., Dorlo, T. P. C., Huitema, A. D. R., & Hendrikx, J. J. M. A. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00821-7 · Cited by 23
Shortwave Infrared-Emitting Theranostics for Breast Cancer Therapy Response Monitoring
Shah, J. V., Gonda, A., Pemmaraju, R., Subash, A., Mendez, C. B., Berger, M., Zhao, X., He, S., Riman, R. E., Tan, M. C., et al. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.569415 · Cited by 21
“In 2018, the United States Food and Drug Administration approved the theranostic Lutathera R©, a Lutetium (Lu) 177-conjugated somatostatin receptor-targeting drug for neuroendocrine tumors (Hennrich and Kopka, 2019).”
BackgroundZhang, D., He, T., Shi, T., Huang, K., & Peng, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1553853 · Cited by 33
Radiolabeled peptide probe for tumor imaging
Yan, Y.-Q., Wang, H., & Zhao, Y. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.02.016 · Cited by 20
Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors
Anderson, R., Velez, E. M., Desai, B., & Jadvar, H. (2021) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-020-00677-0 · Cited by 22
The production and separation of 161Tb with high specific activity at the University of Utah
Holiski, C. K., Bender, A. A., Monte, P. F., Hennkens, H. M., Embree, M. F., Wang, M.-J., Sjoden, G. E., & Mastren, T. (2024) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2024.111530 · Cited by 19
Grzmil, M., Boersema, P. J., Sharma, A. A., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01343-y · Cited by 18
“In 2018, FDA-approved lutathera for the firstin-class peptide receptor radionuclide therapy (PRRT) of somatostatin receptor-positive gastroenteropancreatic and neuroendocrine tumors and, recently, pluvicto has been approved for targeted radioligand therapy of PSMA-positive, metastatic castration-resistant prostate can…”
BackgroundTherapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
McClellan, K. V., Chen, E. Y.-S., Kardosh, A., Lopez, C. D., Rivero, J. D., Mallak, N., Rocha, F. G., Koethe, Y., Pommier, R. F., Mittra, E., et al. (2022) · Cancers · doi:10.3390/cancers14194769 · Cited by 21
Raheem, S. J., Salih, A. K., Garcia, M. D., Sharpe, J. C., Toosi, B. M., & Price, E. W. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00007 · Cited by 20
Yu, Z., Jiang, Z., Cheng, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116787 · Cited by 18
Huangfu, Z., Yang, J., Sun, J., Xu, B., Tao, L., Wu, J., Wang, F., Wang, G., Meng, F., & Zhong, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.040 · Cited by 20
Shalgunov, V., Engudar, G., Bohrmann, L., Wharton, L., Maskell, K., Johann, K., Barz, M., Schaffer, P. C., Herth, M. M., & Radchenko, V. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.11.001 · Cited by 18
Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers
Kalaba, P., de la Rosa, C. S., Möller, A., Alewood, P. F., & Muttenthaler, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01089 · Cited by 19
Kim, J., Choi, Y., Park, J., et al. (2024) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-024-00095-5 · Cited by 17
“For example, Lu-dotatate (Lutathera), the first PDC approved by the US FDA, is used to treat gastrointestinal, pancreatic, and neuroendocrine tumors [50].”
Zareei, S., Khorsand, B., Dantism, A., Zareei, N., Asgharzadeh, F., Zahraee, S. S., Kashan, S. M., Hekmatirad, S., Amini, S., Ghasemi, F., et al. (2024) · Database · doi:10.1093/database/baae092 · Cited by 24
“Despite the development of vaccines and drugs such as Cer-varix, Gardasil [27], Lutathera [28], Padcev [29], and Polivy [30], anticancer peptides have limitations in terms of their efficacy, specificity, and toxicity.”
BackgroundCombination Therapies with PRRT
Yordanova, A., & Ahmadzadehfar, H. (2021) · Pharmaceuticals · doi:10.3390/ph14101005 · Cited by 20
Radiopharmaceuticals for Neuroendocrine Tumors
Chin, R.-I., Wu, F. S., Menda, Y., & Kim, H. J. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.007 · Cited by 18
Machulkin, A. E., Petrov, S. A., Bodenko, V., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00070 · Cited by 16
van der Heide, C. D., Campeiro, J. D., Ruigrok, E. A. M., van den Brink, L., Ponnala, S., Hillier, S., & Dalm, S. U. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01191-6 · Cited by 19
“With FAP-TRT the cancer cells are generally targeted indirectly via the FAP-expressing CAFs, in contrast to currently approved TRT strategies (e.g., targeting somatostatin receptor subtype 2) [11].”
Kwon, D., Takata, K., Zhang, Z., Chong, L. C., Fraser, B., Zeisler, J., Miyata‐Takata, T., Merkens, H., Rousseau, J., Aoki, T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3284 · Cited by 21
“The success of this approach is exemplified by the development of somatostatin- and prostate-specific membrane antigen-targeting radiopharmaceuticals (21, 22).”
BackgroundKanellopoulos, P., Nock, B. A., Greifenstein, L., Baum, R. P., Roesch, F., & Μάινα, Θ. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314590 · Cited by 15
Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors
Shi, C., & Morse, M. A. (2022) · Cancers · doi:10.3390/cancers14246114 · Cited by 16
The role of serotonin inhibition within the treatment of carcinoid syndrome
George, J., Ramage, J. K., White, B. E., & Srirajaskanthan, R. (2023) · Endocrine Oncology · doi:10.1530/eo-22-0077 · Cited by 17
“This paved the way for the approval of Lutathera® (177Lu-DOTA-TATE) by the EMA in 2017 and the FDA in 2018 (Hennrich & Kopka 2019).”
Background[18F]FET-βAG-TOCA: The Design, Evaluation and Clinical Translation of a Fluorinated Octreotide
Allott, L., Dubash, S., & Aboagye, E. O. (2020) · Cancers · doi:10.3390/cancers12040865 · Cited by 15
Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment
Nsereko, Y., Armstrong, A. J., Coburn, F., & Musaimi, O. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146815 · Cited by 16
“Ad-ministered intravenously, it leverages peptide-mediated targeting for precise radionuclide delivery [139].”
Copper-Mediated Radiobromination of (Hetero)Aryl Boronic Pinacol Esters
Mixdorf, J. C., Hoffman, S. L. V., Aluicio‐Sarduy, E., Barnhart, T. E., Engle, J. W., & Ellison, P. A. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c02420 · Cited by 15
Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future
Echavidre, W., Fagret, D., Faraggi, M., Picco, V., & Montemagno, C. (2023) · Cancers · doi:10.3390/cancers15194839 · Cited by 17
Production and purification of 43Sc and 47Sc from enriched [46Ti]TiO2 and [50Ti]TiO2 targets
Cingoranelli, S. J., Bartels, J. L., Kankanamalage, P. H. A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-49377-7 · Cited by 14
Whetter, J. N., Śmiłowicz, D., & Boros, E. (2024) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00781 · Cited by 13
Michler, E., Kästner, D., Pretze, M., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07269-0 · Cited by 14
“…commonly used radiopharmaceutical used in PRRT is [ 177 Lu]Lu-DOTA-TATE, which outperformed long-acting octreotide admin-istrations in a prospective phase three trial and was therefore approved by the European Medicines Agency and US Food and Drug Administration in 2017 and 2018, respectively [2].”
Phase 0 Radiopharmaceutical–Agent Clinical Development
Kunos, C. A., Rubinstein, L., Capala, J., & McDonald, M. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01310 · Cited by 14
Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy
Zhang, S., Zhang, A., Qi, X., Han, Z., Song, L., Zhou, J., Wang, G., Zhu, R., & Li, J. (2025) · Biomimetics · doi:10.3390/biomimetics10060394 · Cited by 19
Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide
Ferreira, C. A., Heidari, P., Ataeinia, B., Sinevici, N., Granito, A., Kumar, H. M., Wehrenberg-Klee, E. P., & Mahmood, U. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071460 · Cited by 14
Alsadik, S., Gnanasegaran, G., Chen, L., Quigley, A., Mandair, D., Toumpanakis, C., Caplin, M. E., & Navalkissoor, S. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13210 · Cited by 14
“The Neuroendocrine Tumors Therapy (NETTER-1) study4,5 was a multicentre, phase III randomised control trial comparing 177Lu-DOTATATE with high dose octreotide long acting repeatable (LAR) in progressive metastatic midgut NETs.”
BackgroundInfluentialRitawidya, R., Wongso, H., Effendi, N., Pujiyanto, A., Lestari, W., Setiawan, H., & Humani, T. S. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.079 · Cited by 15
“80 Lutathera® is the first PRRT radiopharmaceutical and was approved by The European Medicines Agency (EMA) in 2017 and by The Food and Drug Administration (FDA) in 2018.”
BackgroundZambra, M., Ranđelović, I., Talarico, F., Borbély, A., Svajda, L., Tóvári, J., Mező, G., Bodero, L., Colombo, S., Arrigoni, F., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1215694 · Cited by 15
Winter, R., Amghar, M., Wacker, A. S., Bakos, G., Taş, H., Roscher, M., Kelly, J. M., & Benešová, M. (2024) · Pharmaceuticals · doi:10.3390/ph17081031 · Cited by 20
“…in neuroendocrine tumors and [ 177 Lu]Lu-PSMA-617 (Pluvicto ® , FDA-approved in 2022, Novartis) in metastatic castration-resistant prostate cancer (mCRPC) [8–11] promoted the integration of TRNT into standard-of-care (SoC) practices for an even greater variety of cancer types and patients.”
BackgroundTranslating a radiolabeled imaging agent to the clinic
Griffiths, G. L., Vasquez, C., Escorcia, F. E., Clanton, J. A., Lindenberg, L., Mena, E., & Choyke, P. L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114086 · Cited by 14
Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now
Naik, M., AL-NAHHAS, A. M., & Khan, S. R. (2022) · Cancers · doi:10.3390/cancers14030761 · Cited by 17
An 211At-labeled Tetrazine for Pretargeted Therapy
Herth, M. M., Hvass, L., Poulie, C. B. M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02281 · Cited by 12
Kauffman, N., Morrison, J., O’Brien, K., Fan, J., & Zinn, K. R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041138 · Cited by 15
Njotu, F. N., Ketchemen, J. P., Tikum, A. F., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265997 · Cited by 12
Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumab
Rudd, S. E., Zuylekom, J. V., Cullinane, C. M., Blyth, B. J., & Donnelly, P. S. (2025) · Chemical Science · doi:10.1039/d4sc06969b · Cited by 16
Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics
Khan, A., Dias, F., Neekhra, S., Singh, B., & Srivastava, R. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2020.631351 · Cited by 14
Broqueza, J., Prabaharan, C. B., Allen, K. J. H., et al. (2021) · Pharmaceuticals · doi:10.3390/ph15010010 · Cited by 12
Kumar, S., Melek, M., & Rohl, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.906012 · Cited by 13
Nguyen, N. T., Min, Y., Rivière, J., van der Garde, M., Ghosh, S. C., Bartos, L. M., Brendel, M., Bassermann, F. C., Azhdarinia, A., Weber, W., et al. (2025) · Theranostics · doi:10.7150/thno.113354 · Cited by 17
“…177 Lu-DOTA-JR11 (phase I/II clinical evaluation; NCT02592707 [27], NCT04997317, ACTRN12623000 185662), we also synthesized multimodal analogs of an additional agonist ( 177 Lu-DOTA-TATE, clinically approved for NET treatment) [29] and antagonist ( 177 Lu-DOTA-LM3, first-in-human evaluation) [30].”
Leupe, H., Cauwenbergh, M., Cleeren, F., Dekervel, J., Verslype, C., & Deroose, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18111608 · Cited by 15
“Following the results of the NETTER-1 trial, the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approved [ 177 Lu]Lu-DOTATATE as a second-line systemic therapy in GEP-NET patients with positive SSTR expression in 2017 and 2018, respectively [22].”
InfluentialAn Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)
Vishakha, S., Navneesh, N., Kurmi, B. D., Gupta, G. D., Verma, S. K., Jain, A., & Patel, P. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206259585240105051941 · Cited by 12
PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview
Filippi, L., Urso, L., & Evangelista, L. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040190 · Cited by 13
“As a matter of fact, two 177 Lu-based radiopharmaceuticals, Luthathera TM and Pluvicto TM , have been approved by regulatory authorities for clinical use in the last several years [6,7].”
BackgroundKashyap, R. K., Raja, S., Adusumilli, A. K., et al. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13425 · Cited by 11
Tamborino, G., Perrot, Y., Saint‐Hubert, M. D., Struelens, L., Nonnekens, J., de Jong, M., Konijnenberg, M., & Villagrasa, C. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262610 · Cited by 11
Chatelut, É., Lambert, M., Dierickx, L., Brillouet, S., & Courbon, F. (2022) · Current Radiopharmaceuticals · doi:10.2174/1874471015666211228123525 · Cited by 12
Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model
Shim, K., Longtine, M. S., Abou, D. S., Hoegger, M. J., Laforest, R. A., Thorek, D. L. J., & Wahl, R. L. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264816 · Cited by 11
“labeled agents for prostate cancer treatment (Pluvicto®, (6) and neuroendocrine tumors (Lutathera®, (7).”
BackgroundNock, B. A., Kanellopoulos, P., Moon, E. S., Rouchota, M. G., Loudos, G. K., Ballal, S., Yadav, M. P., Bal, C. S., Mishra, P. K., Sheokand, P., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030776 · Cited by 11
The Role of Artificial Intelligence in Advancing Theranostics Dosimetry for Cancer Therapy: a Review
Woo, S. (2025) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-025-00939-9 · Cited by 16
Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide
AghaAmiri, S., Ghosh, S. C., Vargas, S. H., Halperin, D. M., & Azhdarinia, A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00223 · Cited by 11
Theranostic Agent Targeting Bone Metastasis: A Novel [ 68 Ga]Ga/[ 177 Lu]Lu-DOTA-HBED-bisphosphonate
Jin, W., Zhao, R., Wang, R., Choi, S., Plöessl, K., Alexoff, D., Wu, Z., Zhu, L., & Kung, H. F. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02372 · Cited by 12
Konopnicki, A., Zaliznyak, M., Roy, M., & Jana, B. (2024) · Discover Oncology · doi:10.1007/s12672-024-01680-z · Cited by 12
Simón, M., Jørgensen, J. T., Khare, H. A., Christensen, C. L., Nielsen, C. H., & Kjær, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061284 · Cited by 11
Molecular determinants of outcomes in meningiomas
Lynes, J. P., Flores‐Milan, G., Rubino, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962702 · Cited by 10
Gu, J., Wu, Q., Zhang, Q., You, Q., & Wang, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114742 · Cited by 12
Peptide-drug conjugates in tumor therapy: Current advances and future perspectives
Jin, H., Yang, P., Min, H., Song, J., & Qi, Y. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218174 · Cited by 13
A Comprehensive Analysis of Biopharmaceutical Products Listed in the FDA’s Purple Book
Chen, F., Zhong, H., Chan, G., & Ouyang, D. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02802-0 · Cited by 12
“The first-in-class PDC, Lu-177 DOTATATE (Lutathera ® ), also gained approval in 2018, indicated for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [15].”
Design of Cell-Specific Targeting Peptides for Cancer Therapy
Chen, X., Wang, D., Jiang, Y., & Jiang, T. (2024) · Targets · doi:10.3390/targets2030011 · Cited by 12
“Another notable advancement is 177 Lu DOA-TATE [60], the first FDA-approved radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors.”
BackgroundTuncer, O., Steinberger, D. J., Steiner, J. R., Hinojos, M., Rhee, S. Y., Humphrey, B., Jafari, F., & Caycı, Z. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267964 · Cited by 11
Preclinical evaluation of 225Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy
Holzleitner, N., Vilangattil, M. M., Swaidan, A., Garcia-Prada, C. D., Taddio, M. F., Jeanjean, P., Mona, C. E., Lapa, C., Casini, A., Günther, T., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06927-z · Cited by 13
“The field of peptide-based compounds for radioligand therapy (RLT) has provided significant break-throughs and has since been rapidly progressing as a viable option for cancer treatment [1, 2].”
Galbiati, A., Bocci, M., Neri, D., & Cazzamalli, S. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06969-3 · Cited by 11
Advances in radiopharmaceuticals for precision medicine: A global and Chinese perspective
Huang, Q., & Huang, G. (2024) · LabMed discovery. · doi:10.1016/j.lmd.2024.100031 · Cited by 12
Dynamic Visualization of Computer-Aided Peptide Design for Cancer Therapeutics
Hou, D., Zhou, H., Tang, Y., Liu, Z., Su, L., Guo, J., Pathak, J. L., & Wu, L. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s497126 · Cited by 10
Cancer-targeting drug conjugates drives a new era in precise cancer treatment
Deng, J., Shi, J., Li, D., Jiao, X., Liu, J., Tian, H., Liu, N., Luo, C., Kamei, K., & Tian, C. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.110960 · Cited by 11
Novel bio-carriers for radionuclide delivery in cancer radiotherapy
Wang, L., He, Q., Man, J., Gao, Y., Zhou, G., Si, H., Yang, K., Hu, L. T., & Pei, P. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216557 · Cited by 10
Koustoulidou, S., Handula, M., de Ridder, C., Stuurman, D. C., Beekman, S., de Jong, M., Nonnekens, J., & Seimbille, Y. (2022) · Pharmaceuticals · doi:10.3390/ph15091155 · Cited by 9
Chemo-radiotherapy with 177Lu-PLGA(RGF)-CXCR4L for the targeted treatment of colorectal cancer
Cruz-Nova, P., Gibbens-Bandala, B., Ancira-Cortez, A., Ramírez-Nava, G., Santos‐Cuevas, C., Luna‐Gutiérrez, M., & Ocampo‐García, B. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1191315 · Cited by 11
Kayal, G., Van, B., Andl, G., Tu, C., Wareing, T. A., Wilderman, S. J., Mikell, J. K., & Dewaraja, Y. K. (2024) · Medical Physics · doi:10.1002/mp.16996 · Cited by 9
Rahimi, M. N., Corlett, A., Zuylekom, J. V., Sani, M., Blyth, B. J., Thompson, P. E., Roselt, P. D., & Haskali, M. B. (2024) · Theranostics · doi:10.7150/thno.89701 · Cited by 10
“These include the use of radioprotectors, utilizing albumin-binding moieties, and competitive inhibition via co-administration of positively charged amino acids such as L-lysine and L-arginine [60, 61].”
BackgroundKusne, Y. N., Lasho, T. L., Finke, C. M., Elsabbagh, Z., McCue, S. A., Hobday, T. J., Starr, J. S., Bekaii‐Saab, T., Halfdanarson, T. R., Patnaik, M. M., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00143 · Cited by 13
Ларенков, А. А., Mitrofanov, Y. A., & Rakhimov, M. G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121535 · Cited by 8
Bo, Q., Zhang, M., Yang, F., Zheng, Y., Li, Z., Zheng, Y., Wu, F., Liang, J., Zhou, L. Q., Li, D., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01584-w · Cited by 9
Perrone, E., Calcagni, M. L., Leccisotti, L., Moretti, R., Ghai, K., Eismant, A., Parkar, T., Greifenstein, L., & Baum, R. P. (2025) · Cancers · doi:10.3390/cancers17183070 · Cited by 8
Radiolabelled Cyclic Bisarylmercury: High Chemical and in vivo Stability for Theranostics
Gilpin, I. M. F., Ullrich, M., Wuensche, T. E., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100131 · Cited by 8
Kayal, G., Barbosa, N., Marín, C. F. C., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265340 · Cited by 8
Souche, C., Fouillet, J., Rubira, L., Donzé, C., Deshayes, E., & Fersing, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010462 · Cited by 10
“…in the management of neuroendocrine tumors (DOTATOC and DOTATATE vector molecules) [28,29] and metastatic prostate cancer (PSMA ligands vector molecules) [30,31]. tumors DOTATOC and DOTATATE vector molecules ,29] and metastatic prostate cancer (PSMA ligands vector molecules) [30,31].”
BackgroundPreclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma
Waked, A., Crabbé, M., Neirinckx, V., Pérez, S. R., Wellens, J., Rogister, B., Benotmane, M. A., & Vermeulen, K. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00282-y · Cited by 10
t Bu 4 octapa-alkyl-NHS for metalloradiopeptide preparation
Li, L., Kuo, H., Wang, X., et al. (2020) · Dalton Transactions · doi:10.1039/d0dt00845a · Cited by 8
Gilardoni, E., Zana, A., Galbiati, A., et al. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01104 · Cited by 8
Adverse reactions to therapeutic radiopharmaceuticals
Silindir‐Gunay, M., & Ozolmez, N. (2024) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2024.111527 · Cited by 7
Hierlmeier, I., Marino, N., Schreck, M.-V., et al. (2024) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.4c03571 · Cited by 7
Metadata
- Authors
- Hennrich, U., & Kopka, K.
- Affiliations
- German Cancer Research Center (DE)
- Corresponding author
- Hennrich, Ute
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2019-07-29
- Volume
- 12
- Issue
- 3
- Pages
- 114
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6789871
- OpenAlex
- W2965362447
- Semantic Scholar
- 541d92ea7d4ff1ddec5cefec2755259d1aa26d0e
- Cited by
- 440
- References
- 26
- Citations by year
- 2026: 58 · 2025: 87 · 2024: 88 · 2023: 61 · 2022: 58 · 2021: 46 · 2020: 38 · 2019: 3
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- 177Lu-DOTATATE, lutetium-177, peptide receptor radionuclide therapy, somatostatin receptors, DOTATATE, gastroenteropancreatic neuroendocrine tumors, radiopharmaceuticals, targeted radionuclide therapy, DNA double-strand breaks, cancer cell death
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1 Structure of [177Lu]Lu-DOTA-TATE (Lutathera®). Simplified writing of complexation [18].](https://figures.cochat.ai/paper-figures/b252f6f0df3d4eceb221f630640ad0bc/lutathera-the-first-fda-and-ema-approved-radiopharmaceutical-for-peptide-figure-1.jpg)
![Figure 2 Simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE.](https://figures.cochat.ai/paper-figures/56d8de000b344458a3f6939340017c5b/lutathera-the-first-fda-and-ema-approved-radiopharmaceutical-for-peptide-figure-2.jpg)